Charcot-Marie-Tooth disease

Acta Neurologica Taiwanica

Volumn 17, Issue 3, 2008, Pages 203-213

  Lee, Yi Chung ^a,b   Chang, Ming Hon ^a,b   Lin, Kon Ping ^b,c  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Charcot Marie Tooth disease; CMT; Hereditary motor and sensory neuropathy; HMSN

Indexed keywords

ASCORBIC ACID; CONNEXIN 32; MYELIN ASSOCIATED GLYCOPROTEIN; MYELIN BASIC PROTEIN; NEUROFILAMENT PROTEIN; NEUROTROPHIN 3; PERIPHERAL MYELIN PROTEIN 22;

ARTICLE; AUTOSOMAL DOMINANT DISORDER; AUTOSOMAL RECESSIVE DISORDER; CHROMOSOME 17P; CHROMOSOME DUPLICATION; CLINICAL TRIAL; DEMYELINATION; DISEASE CLASSIFICATION; EARLY DIAGNOSIS; GENETIC COUNSELING; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; LIFESTYLE MODIFICATION; NERVE INJURY; NONHUMAN; ONSET AGE; POLYMERASE CHAIN REACTION; RISK FACTOR; X CHROMOSOME LINKED DISORDER;

ANIMALS; ASCORBIC ACID; CHARCOT-MARIE-TOOTH DISEASE; DISEASE MODELS, ANIMAL; HUMANS;

EID: 53849116151     PISSN: 10196099     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (84)

1. Berciano J, Combarros O. Hereditary neuropathies. Curr Opin Neurol 2003;16:613-22.
2. Shy ME, Lupski JR, Chance P, et al. Hereditary motor and sensory neuropathies: an overview of clinical, genetic, electrophysiologic, and pathologic features. In: Dyck PJ, Thomas PK, eds. Peripheral Neuropathy, 4rd ed. Philadelphia: Elsevier Saunders, 2005:1094-136.
3. Reilly MM, Hanna MG. Genetic neuromuscular disease. J Neurol Neurosurg Psychiatry 2002; Suppl 2:II12-21.
4. Shy ME, Garbern JY, Kamholz J. Hereditary motor and sensory neuropathies: a biological perspective. Lancet Neurol 2002;1:110-9.
5. Davis CJ, Bradley WG, Madrid R. The peroneal muscular atrophy syndrome: clinical, genetic, electrophysiological and nerve biopsy studies. I. Clinical, genetic and electrophysiological findings and classification. J Genet Hum 1978;26:311-49.
6. Brust JC, Lovelace RE, Devi S. Clinical and electrodiagnostic features of Charcot-Marie-Tooth syndrome. Acta Neurol Scand 1978;Suppl 68:1-142.
7. Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth disease. Clin Genet 1974;6:98-118.
8. Holmberg BH. Charcot-Marie-Tooth's disease in northern Sweden: an epidemiological and clinical study. Acta Neurol Scand 1993;87:416-22.
9. Lin KP, Kwan SY, Chen SY, et al. Generalized neuropathy in Taiwan: an etiologic survey. Neuroepidemiology 1993; 12:257-61.
10. Birouk N, Gouider R, Le Guern E, et al. Charcot-Marie-Tooth disease type 1A with 17p11.2 duplication. Clinical and electrophysiological phenotype study and factors influencing disease severity in 119 cases. Brain 1997;120:813-23.
11. Gabreels-Festen AA, Bolhuis PA, Hoogendijk JE, et al. Charcot-Marie-Tooth disease type 1A: morphological phenotype of the 17p duplication event versus PMP22 point mutations. Acta Neuropathol 1995;90:645-9.
12. Lupski JR, de Oca-Luna RM, Slaugenhaupt S, et al. DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell 1991;66:219-32.
13. Chance PF. Overview of hereditary neuropathy with liability to pressure palsies. Ann N Y Acad Sci 1999;883:14-21.
14. Suter U, Snipes GJ. Peripheral myelin protein 22: facts and hypotheses. J Neurosci Res 1995;40:145-51.
15. Schenone A, Nobbio L, Mandich P, et al. Underexpression of messager RNA for peripheral myelin protein 22 in hereditary neuropathy with liability to pressure palsies. Neurology 1997;48:445-9.
16. Yoshikawa H, Nishimura T, Nakatsuji Y, et al. Elevated expression of messenger RNA for peripheral myelin protein 22 in biopsied peripheral nerves of patients with Charcot-Marie-Tooth disease type 1A. Ann Neurol 1994; 35:445-50.
17. Gabriel JM, Erne B, Pareyson D, et al. Gene dosage effects in hereditary peripheral neuropathy. Expression of peripheral myelin protein 22 in Charcot-Marie-Tooth disease type 1A and hereditary neuropathy with liability to pressure palsies nerve biopsies. Neurology 1997;49:1635-40.
18. Sereda M, Griffiths I, Pühlhofer A, et al. A transgenic rat model of Charcot-Marie-Tooth disease. Neuron 1996; 16:1049-60.
19. Magyar JP, Martini R, Ruelicke T, et al. Impaired differentiation of Schwann cells in transgenic mice with increased PMP22 gene dosage. J Neurosci 1996;16:5351-60.
20. Valentijn LJ, Baas F, Wolterman RA, et al. Identical point mutations of PMP-22 in Trembler-J mouse and Charcot-Marie-Tooth disease type 1A. Nat Genet 1992;2:288-91.
21. Roa BB, Dyck PJ, Marks HG, et al. Dejerine-Sottas syndrome associated with point mutation in the peripheral myelin protein 22 (PMP22) gene. Nat Genet 1993;5:269-73.
22. Simonati A, Fabrizi GM, Pasquinelli A, et al. Congenital hypomyelination neuropathy with Ser72Leu substitution in PMP22. Neuromuscul Disorder 1999;9:257-61.
23. Sanders CR, Ismail-Beigi F, McEnery MW. Mutations of peripheral myelin protein 22 result in defective trafficking through mechanisms which may be common to diseases involving tetraspan membrane proteins. Biochemistry 2001;40:9453-9.
24. 0 gene. Nat Genet 1993;5:31-4.
25. 0 protein as a homophilic adhesion molecule. Nature 1990; 344:871-2.
26. 0 gene in Dejerine-Sottas disease (hereditary motor and sensory neuropathy type III). Nat Genet 1993;5:266-8.
27. 0) mutations may include Charcot-Marie-Tooth type 1B, Dejerine-Sottas, and congenital hypomyelination. Neuron 1996;17:451-60.
28. Marrosu MG, Vaccargiu S, Marrosu G, et al. Charcot-Marie-Tooth disease type 2 associated with mutation of the myelin protein zero gene. Neurology 1998;50:1397-401.
29. Mastaglia FL, Nowak KJ, Stell R, et al. Novel mutation in the myelin protein zero gene in a family with intermediate hereditary motor and sensory neuropathy. J Neurol Neurosurg Psychiatry 1999;67:174-9.
30. Donaghy M, Sisodiya SM, Kennett R, et al. Steroid responsive polyneuropathy in a family with a novel myelin protein zero mutation. J Neurol Neurosurg Psychiatry 2000; 69:799-805.
31. Shy ME, Jani A, Krajewski K, et al. Phenotypic clustering in MPZ mutations. Brain 2004;127:371-84.
32. 0 interacts with negatively charged phospholipid bilayers. J Biol Chem 1994;269:10764-70.
33. 0 protein truncated in its cytoplasmic domain. J Cell Biol 1996;134:1531-41.
34. Matsuyama W, Nakagawa M, Takashima H, et al. Altered trafficking and adhesion function of MPZ mutations and phenotypes of Charcot-Marie-Tooth disease 1B. Acta Neuropathol 2002;103:501-8.
35. Lee YC, Yu CT, Lin KP, et al. MPZ mutation G123S characterization: evidence for a complex pathogenesis in CMT disease. Neurology 2008;70:273-7.
36. 0-GFP fusion proteins. BMC Cell Biol 2002;3:29.
37. Konde V, Eichberg J. Myelin protein zero: mutations in the cytoplasmic domain interfere with its cellular trafficking. J Neurosci Res 2006;83:957-64.
38. 0) mutations associated with Charcot-Marie-Tooth-related disease. J Neuropathol Exp Neurol 2003; 62:751-64.
39. 0)-deficient mice show myelin degeneration in peripheral nerves characteristic of inherited human neuropathies. Nat Genet 1995; 11:281-6.
40. Starr A, Michalewski HJ, Zeng FG, et al. Pathology and physiology of auditory neuropathy with a novel mutation in the MPZ gene (Tyrl45-->Ser). Brain 2003;126:1604-19.
41. Kovach MJ, Lin JP, Boyadjiev S, et al. A unique point mutation in the PMP22 gene is associated with Charcot-Marie-Tooth disease and deafness. Am J Hum Genet 1999; 64:1580-93.
42. Sambuughin N, de Bantel A, McWilliams S, et al. Deafness and CMT disease associated with a novel four amino acid deletion in the PMP22 gene. Neurology 2003;60:506-8.
43. Street VA, Bennett CL, Goldy JD, et al. Mutation of a putative protein degradation gene LITAF/SIMPLE in Charcot-Marie-Tooth disease 1C. Neurology 2003;60:22-6.
44. Myokai F, Takashiba S, Lebo R, et al. A novel lipopolysaccharide-induced transcription factor regulating tumor necrosis factor alpha gene expression: molecular cloning, sequencing, characterization, and chromosomal assignment. Proc Natl Acad Sci USA 1999;96:4518-23.
45. Warner LE, Mancias P, Butler IJ, et al. Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathies. Nat Genet 1998;18:382-4.
46. Nagarajan R, Svaren J, Le N, et al. EGR2 mutations in inherited neuropathies dominant-negatively inhibit myelin gene expression. Neuron 2001;30:355-68.
47. Timmerman V, De Jonghe P, Ceuterick C, et al. Novel mis-sense mutation in the early growth response 2 gene associated with Dejerine-Sottas syndrome phenotype. Neurology 1999;52:1827-32.
48. Topilko P, Schneider-Maunoury S, Levi G, et al. Krox-20 controls myelination in the peripheral nervous system. Nature 1994;371:796-9.
49. Mersiyanova IV, Perepelov AV, Polyakov AV, et al. A new variant of Charcot-Marie-Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene. Am J Hum Genet 2000;67:37-46.
50. Jordanova A, De Jonghe P, Boerkoel CF, et al. Mutations in the neurofilament light chain gene (NEFL) cause early onset severe Charcot-Marie-Tooth disease. Brain 2003; 126:590-7.
51. Perez-Olle R, Jones ST, Liem RK. Phenotypic analysis of neurofilament light gene mutations linked to Charcot-Marie-Tooth disease in cell culture models. Hum Mol Genet 2004;13:2207-20.
52. Kriz J, Zhu Q, Julien JP, et al. Electrophysiological properties of axons in mice lacking neurofilament subunit genes: disparity between conduction velocity and axon diameter in absence of NF-H. Brain Res 2000;885:32-44.
53. Zhu Q, Couillard-Despres S, Julien JP. Delayed maturation of regenerating myelinated axons in mice lacking neurofilaments. Exp Neurol 1997;148:299-316.
54. Bergoffen J, Scherer SS, Wang S, et al. Connexin mutations in X-linked Charcot-Marie-Tooth disease. Science 1993; 262:2039-42.
55. Scherer SS, Kleopa KA. X-linked Charcot-Marie-Tooth diease. In: Dyck PJ, Thomas PK, eds. Peripheral Neuropathy, 4rd ed. Philadelphia: Elsevier Saunders, 2005: 1094-36.
56. Kumar NM, Gilula NB. The gap junction communication channel. Cell 1996;84:381-8.
57. Kleopa KA, Zamba-Papanicolaou E, Alevra X, et al. Phenotypic and cellular expression of two novel connexin32 mutations causing CMT1X. Neurology 2006;66:396-402.
58. Song S, Zhang Y, Chen B, et al. Mutation frequency for Charocot-Marie-Tooth disease type 1 in the Chinese population is similar to that in the global ethnic patients. Genet Med 2006;8:532-5.
59. Park HK, Kim BJ, Sung DH, et al. Mutation analysis of the PMP22, MPZ, EGR2, LITAF, and GJB1 genes in Korean patients with Charcot-Marie-Tooth neuropathy type 1. Clin Genet 2006;70:253-6.
60. Numakura C, Shirahata E, Yamashita S, et al. Screening of the early growth response 2 gene in Japanese patients with Charcot-Marie-Tooth disease type 1. J Neurol Sci 2003; 210:61-4.
61. Mostacciuolo ML, Righetti E, Zortea M, et al. Charcot-Marie-Tooth disease type 1 and related demyelinating neuropathies: Mutation analysis in a large cohort of Italian families. Hum Mutat 2001;18:32-41.
62. Mersiyanova IV, Ismailov SM, Polyakov AV, et al. Screening for mutations in the peripheral myelin genes PMP22, MPZ and CX32 (GJB1) in Russian Charcot-Marie-Tooth neuropathy patients. Hum Mutat 2000;15:340-7.
63. Wise CA, Garcia CA, Davis SN, et al. Molecular analyses of unrelated Charcot-Marie-Tooth (CMT) disease patients suggest a high frequency of the CMT1A duplication. Am J Hum Genet 1993:53:853-63.
64. Lupski JR, de Oca-Luna RM, Slaugenhaupt S, et al. DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell 1991;66:219-32.
65. Shaffer LG, Kennedy GM, Spikes AS, et al. Diagnosis of CMT1A duplications and HNPP deletions by interphase FISH: implications for testing in the cytogenetics laboratory. Am J Med Genet 1997;69:325-31.
66. Chang JG, Jong YJ, Wang WP, et al. Rapid detection of a recombinant hotspot associated with Charcot-Marie-Tooth disease type 1A duplication by a PCR-based DNA test. Clin Chem 1998;44:270-4.
67. Latour P, Boutrand L, Levy N, et al. Polymorphic short tandem repeats for diagnosis of the Charcot-Marie-Tooth 1A duplication. Clin Chem 2001;47:829-37.
68. Thiel CT, Kraus C, Rauch A, et al. A new quantitative PCR multiplex assay for rapid analysis of chromosome 17p11.2-12 duplications and deletions leading to HMSN/HNPP. Eur J Hum Genet 2002;11:170-8.
69. Wilke K, Duman B, Horst J. Diagnosis of haploidy and triploidy based on measurement of gene copy number by real-time PCR. Hum Mutat 2000;16:431-6.
70. Aarskog NK, Vedeler CA. Real-time quantitative polymerase chain reaction. A new method that detects both the peripheral myelin protein 22 duplication in Charcot-Marie-Tooth type 1A disease and the peripheral myelin protein 22 deletion in hereditary neuropathy with liability to pressure palsies. Hum Genet 2000;107:494-8.
71. Slater H, Bruno D, Ren H, et al. Improved testing for CMT1A and HNPP using multiplex ligation-dependent probe amplification (MLPA) with rapid DNA preparations: comparison with the interphase FISH method. Hum Mutat 2004;24:164-71.
72. Hsieh SY, Kuo HC, Chu CC, et al. Charcot-Marie-Tooth disease type 1A: a clinical, electrophysiological, pathological, and genetic study. Chang Gung Med J 2004;27:300-6.
73. Tsai YT, Kuo HC, Chu CC, et al. Hereditary neuropathy with liability to pressure palsies: a clinical and genetic study of a Taiwanese family. Chang Gung Med J 2005;28: 56-63.
74. Lin KP, Chou CH, Lee HY, et al. Allele-specific all-or-none PCR product diagnostic strategy for Charcot-Marie-Tooth 1A and hereditary neuropathy with liability to pressure palsies. J Chin Med Assoc 2006;69:68-73.
75. Lin CY, Su YN, Lee CN, et al. A rapid and reliable detection system for the analysis of PMP22 gene dosage by MP/DHPLC assay. J Hum Genet 2006;51:227-35.
76. Hung CC, Lee CN, Lin CY, et al. Identification of deletion and duplication genotypes of the PMP22 gene using PCR-RFLP, competitive multiplex PCR, and multiplex ligation-dependent probe amplification: a comparison. Electrophoresis 2008;29:618-25.
77. Chen SR, Lin KP, Kuo HC, et al. Comparison of two PCR-based molecular methods in the diagnosis of CMT1A and HNPP disease in Chinese. Clin Neurol Neurosurg 2008; 110:466-71.
78. Wang HL, Wu T, Chang WT, et al. Point mutation associated with X-linked dominant Charcot-Marie-Tooth disease impairs the P2 promoter activity of human connexin-32 gene. Brain Res Mol Brain Res 2000;78:146-53.
79. Wu T, Wang HL, Chu CC, et al. Clinical and electrophysiological studies of a family with probable X-linked dominant Charcot-Marie-Tooth neuropathy and ptosis. Chang Gung Med J 2004;27:489-500.
80. Wang HL, Chang WT, Yeh TH, et al. Functional analysis of connexin-32 mutants associated with X-linked dominant Charcot-Marie-Tooth disease. Neurobiol Dis 2004;15:361-70.
81. Lee YC, Soong BW, Lin KP, et al. Myelin protein zero gene mutations in Taiwanese patients with Charcot-Marie-Tooth disease type 1. J Neurol Sci 2004;219:95-100.
82. Lee YC, Soong BW, Liu YT, et al. Median nerve motor conduction velocity is concordant with myelin protein zero gene mutation. J Neurol 2005;252:151-5.
83. Passage E, Norreel JC, Noack-Fraissignes P, et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med 2004;10:396-401.
84. Sahenk Z, Nagaraja HN, McCracken BS, et al. NT-3 promotes nerve regenerations and sensory improvement in CMT1A mouse models and in patients. Neurology 2005; 65:681-9.